Nexium Case Begins To Define Contours Of Actavis Decision
September 27, 2013, 11:52 AM EDT
Law360, New York (September 27, 2013, 11:52 AM EDT) -- Recently, a federal judge in Massachusetts largely denied a series of motions seeking dismissal of various “pay-for-delay” claims brought by direct and indirect purchasers involving AstraZeneca PLC's acid reflux drug Nexium. Although certain federal and state claims were trimmed on statute of limitations grounds, U.S. District Judge William Young let stand the core claims of the suit based on the alleged continuing harm flowing from the agreements.
This ruling comes just months after the U.S. Supreme Court's long-awaited decision in Federal Trade Commission v. Actavis, and...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.